AR and prostate carcinoma: Furthermore, a study regarding to androgen receptor splice variant AR-V7 indicated that DDX39B could serve as the accelerator of AR-V7 mRNA expression and escalated DDX39B could result in resistance to androgen deprivation therapy and poor prognosis in patients with prostate cancer (Nakata et al., 2017).